Always been the problem and never really been answ
Post# of 36568
(Total Views: 239)
Posted On: 02/16/2020 6:37:51 AM
Always been the problem and never really been answered other than Generex killed credibility under the previous management.
Too many failures or lack of follow through on projects. Burned through hundreds and hundreds of millions of $ in the process. Eventually couldn't raise any money so it went dark for a good period.
NGIO getting re-valued at somewhere around 800M would be a huge plus. Remember this time, it is not just a Generex paid for appraisal being done on AE37. Merck is involved(kind of). There is an investment banker involved. Lends significant credibility to the process. We have new studies to promote, an existing Chinese pharma partner and pending corana virus platform and new partnership to add value.
My concern for NGIO. Being majority owned by Generex. Every body knows it. Is NGIO going to get the benefit of the doubt most other small biotechs have and trade at their potential?
I fear the good news for NGIO about corona virus test kits and vaccine is being wasted because the spin out hasn't happened. The effect for GNBT may be muted in comparison to what would have happened for NGIO. Potentially hundreds of millions of dollars of shareholder value for NGIO. I hope the value gets added into the IPO pricing.
Too many failures or lack of follow through on projects. Burned through hundreds and hundreds of millions of $ in the process. Eventually couldn't raise any money so it went dark for a good period.
NGIO getting re-valued at somewhere around 800M would be a huge plus. Remember this time, it is not just a Generex paid for appraisal being done on AE37. Merck is involved(kind of). There is an investment banker involved. Lends significant credibility to the process. We have new studies to promote, an existing Chinese pharma partner and pending corana virus platform and new partnership to add value.
My concern for NGIO. Being majority owned by Generex. Every body knows it. Is NGIO going to get the benefit of the doubt most other small biotechs have and trade at their potential?
I fear the good news for NGIO about corona virus test kits and vaccine is being wasted because the spin out hasn't happened. The effect for GNBT may be muted in comparison to what would have happened for NGIO. Potentially hundreds of millions of dollars of shareholder value for NGIO. I hope the value gets added into the IPO pricing.
(4)
(0)